DexCom Free cash flow increased by 133.7% to $449.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 363.8%, from $96.80M to $449.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 112.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$39.60M | $139.20M | $25.60M | -$30.60M | $81.30M | $185.00M | $69.00M | $80.70M | $131.30M | $218.80M | $81.10M | $152.30M | $213.30M | $88.30M | $176.80M | $96.80M | $208.90M | $579.40M | $192.10M | $449.00M |
| QoQ Change | — | +451.5% | -81.6% | -219.5% | +365.7% | +127.6% | -62.7% | +17.0% | +62.7% | +66.6% | -62.9% | +87.8% | +40.1% | -58.6% | +100.2% | -45.2% | +115.8% | +177.4% | -66.8% | +133.7% |
| YoY Change | — | — | — | — | +305.3% | +32.9% | +169.5% | +363.7% | +61.5% | +18.3% | +17.5% | +88.7% | +62.5% | -59.6% | +118.0% | -36.4% | -2.1% | +556.2% | +8.7% | +363.8% |